CannaPacific

CannaPacific’s mission is to improve people’s lives by attaining a world-leading position in the field of cannabinoid science through the research, development and commercialisation of cannabinoid molecules as authorised pharmaceutical products.

Investor Presentation

Want more information about this exciting opportunity

Evidence Matters

“This is a pivotal time in the world of cannabis policy and research.”

National Academies of Sciences, Engineering, and Medicine 2017. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research.

“Cannabinoids are a promising method for pharmacological treatment of post-traumatic stress disorder (PTSD).”

Luke J. Ney, Allison Matthews, Raimondo Brunoa, Kim L. Felmingham, Cannabinoid interventions for PTSD: Where to next?, Progress in Neuropsychopharmacology & Biological Psychiatry.

“There is conclusive or substantial evidence that cannabis or cannabinoids are effective… For the treatment of chronic pain in adults”

National Academies of Sciences, Engineering, and Medicine 2017. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research.

December 10, 2020

September 15, 2020

e3D Pharma with the University of New South Wales to research cannabinoid actives for PTSD and Anxiety treatments using translational behavioural models.

July 21, 2021

CannaPacific

CannaPacific’s mission is to improve people’s lives by attaining a world-leading position in the field of cannabinoid science through the research, development and commercialisation of cannabinoid molecules as authorised pharmaceutical products.

Investor Presentation

Want more information about this exciting opportunity

Evidence Matters

“This is a pivotal time in the world of cannabis policy and research.”

“Cannabinoids are a promising method for pharmacological treatment of post-traumatic stress disorder (PTSD).”

“There is conclusive or substantial evidence that cannabis or cannabinoids are effective… For the treatment of chronic pain in adults”

CannaPacific, an Australian biotechnology company focused on the cannabinoid pharmaceutical sector today announced a partnership with the CSIRO, Australia's national science agency, to trial novel encapsulation technologies for more effective medicinal cannabinoids.

December 10, 2020

Billionaire families back early stage medical cannabis company

September 15, 2020

Medicinal cannabis company and Newcastle University researchers aim to breed new varieties with more of the less common cannabinoids

September 15, 2020

e3D Pharma with the University of New South Wales to research cannabinoid actives for PTSD and Anxiety treatments using translational behavioural models.

Novel pain signalling assays for the development of cannabinoid-based medicines

CannaPacific and CSIRO trial novel encapsulation technologies for medicinal cannabinoids

CannaPacific Awarded Permits for Cultivation, Production and Research of Medicinal Cannabis

Partners

We are proud to work with our partners to deliver one of the most advanced cannabis genomic breeding programs in the world

Sign up for Updates

CannaPacific is an Australian biotech company focused on the cannabinoid pharmaceutical sector.

COMPANY LINKS

PATIENT INFORMATION

CONTACT US

Copyrights © 2018 – 2020 | CannaPacific All rights reserved.

Request Info

Enquire now

Request Info